Agilent Technologies, Inc.

Equities

A

US00846U1016

Market Closed - Nyse Other stock markets 04:00:03 2026-05-08 pm EDT			5-day change	1st Jan Change
115.62 ^USD	-2.55%		+0.96%	-15.03%

May. 04	Agilent names Michael Buckner as chief legal officer	RE
May. 04	Agilent Technologies Inc. Appoints Michael Buckner as Chief Legal Officer, Effective May 4, 2026	CI

Transcript : Agilent Technologies, Inc. - Shareholder/Analyst Call

Published on 03/18/2026 at 11:50 am EDT - Modified on 04/10/2026 at 07:05 pm EDT

S&P Capital IQ

Presenter Speech
Bret DiMarco (Executives)

Good morning, everyone, and welcome to Agilent's 2026 Annual Stockholders Meeting. We're glad you can join us today. My name is Bret DiMarco, and I am the

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Agilent Technologies, Inc.

May. 04	Agilent names Michael Buckner as chief legal officer	RE
May. 04	Agilent Technologies Inc. Appoints Michael Buckner as Chief Legal Officer, Effective May 4, 2026	CI
Apr. 22	Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for Keytruda	CI
Apr. 21	Axion BioSystems and Agilent Technologies resolve litigation	RE
Apr. 17	Lunit Presents Six AI Studies At AACR 2026 Highlighting Advances in Precision Oncology and Real-World Clinical Application	CI
Apr. 14	Barclays Adjusts Price Target on Agilent Technologies to $140 From $150, Maintains Overweight Rating	MT
Apr. 13	TD Cowen Adjusts Price Target on Agilent Technologies to $147 From $157, Maintains Buy Rating	MT
Apr. 06	Evercore ISI Adjusts Agilent Technologies Price Target to $140 From $160, Maintains Outperform Rating	MT
Apr. 06	Agilent Technologies, Inc. Announces Executive Changes	CI
Apr. 01	Agilent Technologies Inc Announces the Biotek Cytation 9 Cell Imaging Multimode Reader	CI
Mar. 26	Agilent Says FDA Approves Companion Diagnostic for Esophageal or Gastroesophageal Junction Carcinoma	MT
Mar. 26	Agilent Technologies, Inc. Receives FDA Approval For PD-L1 IHC 22C3 PharmDx In Esophageal Or Gastroesophageal Junction Carcinoma	CI
Mar. 23	Maxcyte, Inc. Appoints Parmeet Ahuja as Chief Financial Officer, Effective March 30, 2026	CI
Mar. 19	Agilent Technologies, Inc. Showcases Advances in Precision Oncology and Digital Pathology at USCAP 2026	CI
Mar. 18	Agilent Technologies, Inc. - Shareholder/Analyst Call